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Abstract 
 1
 There is growing agreement that genetic factors play an important role in the risk to develop 
heroin addiction and comparisons of heroin addiction vulnerability in inbred strains of mice 
could provide useful information on the question of individual vulnerability to heroin 
addiction.  This study examined the rewarding and locomotor stimulating effects of heroin in 
male C57BL/6J and DBA/2J mice.  Heroin induced locomotion and sensitisation in C57BL/6J 
but not in DBA/2J mice. C57BL/6J mice developed conditioned place preference (CPP) to the 
highest doses of heroin, while DBA/2J showed CPP to only the lowest heroin doses, 
indicating a higher sensitivity of DBA/2J mice to the rewarding properties of heroin versus 
C57BL/6J mice.  In order to investigate the neurobiological substrate underlying some of 
these differences, the effect of chronic “intermittent” escalating dose heroin administration on 
the opioid, dopaminergic and stress systems was explored.  Two fold higher μ- opioid 
receptor (MOP-r) stimulated [35S]GTPγS binding was observed in the nucleus accumbens and 
caudate of  saline treated C57BL/6J mice compared to DBA/2J.  Heroin decreased MOP-r 
density in brain regions of C57BL/6J mice, but not in DBA/2J.  Higher density of dopamine 
transporters (DAT) was observed in nucleus accumbens shell and caudate of heroin treated 
DBA/2J mice compared to heroin treated C57BL/6J.  There were no effects on D1 and D2 
binding.  Chronic heroin administration decreased corticosterone levels in both strains with no 
effect of strain.  These results suggest that genetic differences in MOP-r activitation and DAT 
expression may be responsible for individual differences in vulnerability to heroin addiction 
(250 words) 
 
 
 
 
Introduction 
 2
 Heroin is one of the widest abused opiate drug (Pouletty 2002).  There is growing agreement 
that genetic factors play an important role in the risk to develop heroin addiction (Kreek et al. 
2005).  Inbred strains of mice have served as a valuable model to study vulnerability to drugs 
of abuse due to the large inter strain variability in their drug-induced behavioural phenotype 
and the observations clearly suggest that major genetic influences control this effect (Murphy 
et al. 2001; Schlussman et al. 2008).   
 
In this regard, two of the most studied inbred strains of mice are C57BL/6J mice and DBA/2J.  
C57BL/6J mice are considered to be highly sensitive to the rewarding and reinforcing effects 
of alcohol, nicotine an amphetamine, but DBA/2J mice appear to be insensitive to 
amphetamine and alcohol (Belknap et al. 1993; Meliska et al. 1995; Stolerman et al. 1999; 
Cabib et al. 2000; Orsini et al. 2004; Glatt et al. 2009), whereas inconsistent findings have 
been reported for cocaine and morphine (Cunningham et al. 1992; Semenova et al. 1995; 
Orsini et al. 2005).   
  
Although heroin is one of the widest abused opiates (Pouletty 2002), there are limited number 
of studies addressing the effect of genotype on heroin addictive behaviours in inbred strains of 
mice.  There is some evidence suggesting that the pharmacological and behavioural profiles 
of morphine and heroin may differ in respect to analgesia, tolerance and dependence (Rady et 
al. 1991; Rossi et al. 1996; Klein et al. 2008).  This study sought to determine whether the 
rewarding and locomotor stimulating effect of heroin are dependent on genotype by 
comparing the locomotor, sensitisation and CPP responses to heroin in C57BL/6J and 
DBA/2J mice during a paired CPP protocol.   
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The neurobiological substrate underlying the strain differences in opioid abuse sensitivity is 
not clear.  While Berrettini et al., (1994) reported that strain differences in MOP-r density and 
regulation may be responsible for the distinct behavioural phenotypes in response to morphine, 
Doyle et al., (2006) failed to find any significant transcriptional regulation of MOP-r in any of 
these strains.  Moreover, as the stimulatory effects of opiates in rodents has been attributed to 
an increase in dopamine release in the striatum (Di-Chiara & Imperato 1988a; 1988b), it was 
hypothesised that strain differences in opioid induced dopamine release could account for the 
distinct behavioural phenotypes.  Microdialysis studies did not confirm this hypothesis 
(Murphy et al. 2001; Fadda et al. 2005).  Nonetheless, that does not exclude the presence of 
differences in the sensitivity of the D1 and D2 receptors and dopamine transporters (DAT) 
between the two strains.  As a result we hypothesise that strain differences in the sensitivity of 
MOP-r and dopaminergic system or in their regulation by opiates could account for the strain 
differences observed in chronic opiate mediated addictive related behaviours. We carried out 
MOP-r, MOP-r agonist stimulated [35S] guanosine 5’-[γ-[35S]thio]-triphosphate (GTPγS), D1, 
D2 and DAT autoradiography in parallel in brain sections of C57BL/6J and DBA/2J mice 
treated with a  chronic “intermittent” escalating dose heroin administration paradigm.  (495 
words) 
 
Methods 
 
Animals 
 
Male C57BL/6J and DBA/2J mice (B & K Universal Ltd, Hull, UK) weighing 20-25 g were 
used.  Mice were individually housed in a temperature and humidity controlled room with a 
12h light/dark schedule for at least 2 weeks before experiments were begun.  Food and water 
were available at libitum.  All animals were weighed daily throughout the study.  All studies 
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were performed in accordance with protocols approved by the Home Office (Animals Act 
1986) UK and the European Community Council Directive of the 24th Nov 1986 
(86/609/EEC). 
 
Heroin-induced conditioned place preference and sensitization 
 
The place preference of the animals was monitored by the use of the automated CPP 
apparatus, Opto-Max Activity Meter v2.16 (Columbus Instruments, Columbus, OH, USA).  
This apparatus has been previously described by Achat-Mendes (2003).  The apparatus 
consisted of a rectangular Plexiglas box (42 x 20 x 20 cm) divided by a removable guillotine 
door into two chambers of equal size (21 x 20 x 20 cm), one comprising a black floor with 4 
black walls (black compartment) and the other a white floor with black vertical stripes (2 cm) 
with 4 white walls with black vertical stripes (2 cm) (white compartment).  The apparatus was 
covered with a transparent Plexiglas lid perforated to allow adequate ventilation.  A 
transparent colourless, enclosed Plexiglas waiting chamber (12 x 8 x 8 cm) was affixed to one 
side of the CPP cage at the junction of the black and white compartments.  Mice were placed 
in the waiting chamber and allowed entry via a guillotine door.  The cage was equipped with 
matching pairs of horizontal sensors mounted alongside opposing lengths (42 cm long).  The 
black and stripped compartments were scanned at a rate of 10 Hz by 7 infrared beams, spaced 
at 2.54 cm intervals.  A null zone was assigned at the interface of the black and white zones in 
the centre of the box and was monitored by 2 beams. 
 
The CPP experiments were conducted during the light phase of the light-dark cycle (lights on: 
7:00 a.m) and followed  by four sequential phases: habituation, preconditioning test, 
conditioning and postconditioning  test.  Throughout the experiment, the mice were brought 
into the test room 1 h before being tested.  Following habituation (day 1), in which animals 
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had free-access to both compartments of the place preference chambers for 20 min, the mice 
were given a preconditioning test (20 min) (day 2) in which the time spent in the three  
compartments (black, white and null) in the last 15 min of the test was compared to establish 
compartment preference prior to conditioning.  Animals showing strong unconditioned 
aversion (less than 33 % of the session time present in one compartment compared to the 
others) or preference (more than 67% of the session time present in one compartment 
compared to the others)   for any compartment were discarded.  On the following 4 days, two 
conditioning sessions were given daily.  The rectangular Plexiglas box was then divided into 
two equal chambers separated by a removable guillotine door.  At 9:00 a.m., C57BL/6J and 
DBA/2J mice were injected with saline (10 ml/kg, s.c.) and immediately confined to one side 
of the apparatus (a.m. session).  Four hours later, the same animals were injected with heroin 
(Sigma-Aldrich, Poole, Dorset, UK) (0.5, 1, 2, 4 or 8 mg/kg, s.c.) and confined to the opposite 
side of the apparatus (p.m. session).  Always, during each conditioning session, the mice that 
showed initial preference to one chamber were paired with the drug injection in the opposite 
chamber (drug paired with the least preferred side- non counterbalanced biased compartment 
assignment).  Conditioning trials lasted 30 min.  Control animals were included which 
received saline every day.  As described by Szumlinski (2005), locomotor activity was 
monitored during the first and fourth heroin/saline conditioning session when the mice were 
confined to one compartment to assess for strain differences in the development of heroin-
induced locomotor sensitization.  The day after the last conditioning session, a 
postconditioning test session was performed in the undrugged state by allowing free access of 
the mice to all chambers of the apparatus as in the preconditioning session.  Time spent in 
each chamber was recorded for the last 15 min of the 20 min test to establish compartment 
preference after conditioning.  The first 5 min were omitted in our preference testing in order 
to minimize the influence of stress that the mice would experience in their non home cage 
environment on CPP behaviour. 
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 Chronic heroin administration 
 
Following acclimatisation, subcutaneous (s.c.) injections of either saline (10 ml/kg) or heroin 
were then administered to C57BL/6J and DBA/2J mice in a chronic “intermittent”  escalating 
dose paradigm to mimic a common pattern of self-administration in human heroin abusers 
(Kreek et al. 2002).  Animals in the escalating dose group received 2x1 mg/kg/injection on 
day 1, 2x2 mg/kg/injection on days 2 and 3, 2x4 mg/kg/injection on days 4 and 5, and 2x8 
mg/kg/injection on days 6 and 7.  Two subcutaneous injections were given daily (5 p.m and 9 
a.m) , in accordance with a protocol which has been used as an animal model to investigate 
heroin and morphine addictive processes (Spanagel 1995; Muller & Unterwald 2004).   
 
Heroin-induced locomotor activity 
 
Locomotor activity was measured by the use of 12 motility chambers (40cm length x 20 cm 
wide x 20 cm height) (Linton Instrumentation, Norfolk, UK).  Each cage had two sets of 16 
photocells located at right angles to each other, projecting horizontal infrared beams 2.5 cm 
apart and 6 cm above the cage floor.  Locomotor activity was defined as the activity from 
measurement of sequential infrared beam breaks, recorded every 15 min, beginning 
immediately after placing the animals in the cage following an injection of saline or heroin 
and continued for a 2 h period.  For measurement of basal activity, mice were habituated for 
60 min in the motility boxes prior to injections.  The locomotor activity for each mouse 
injected with the 9 a.m injections of saline or heroin was monitored every day for the 7 days 
duration of the study.  
 
μ-(MOP-r), D1, D2 dopamine receptor and dopamine transporter (DAT) autoradiography 
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 Animals were killed 2 h following the last injection of saline or heroin on day 7 of the 
“intermittent” escalating dose heroin administration study described above, and the brains 
were immediately removed, snap frozen at -25 oC and stored at  -80 oC until sectioning.  
Quantitative autoradiography was performed as detailed previously for MOP-r binding  
(Kitchen et al. 1997; Bailey et al. 2002; Bailey et al. 2005; Bailey et al. 2007a; Bailey et al. 
2008), for D1 , D2 dopamine receptor binding (Lena et al. 2004; Bailey et al. 2008) and DAT 
binding (Javitch et al. 1985; Bailey et al. 2008) using the general procedures of Kitchen et al. 
(1997).  Adjacent 20 μm coronal sections were cut at an interval of 300 μm from chronic 
saline or heroin treated C57BL/6J and DBA/2J mice brains for the determination of total and 
non-specific binding of [3H] D-Ala2-MePhe4-Gly-ol5 enkephalin DAMGO (GE Healthcare 
Life Sciences, Bucks, UK), [3H]SCH-23390, [3H]raclopride and [3H]mazindol (Perkin Elmer, 
Bucks, UK) at MOP-r, D1, D2 dopamine receptor and DAT respectively.  Ligand 
concentrations were 3-4 x Kd with all ligands used at a concentration of 4 nM.  Non-specific 
binding was defined in the presence of  naloxone (1 μM) for [3H]DAMGO, and cis-
flupenthixol (10 μM), sulpiride (10 μM), or unlabelled mazindol (10 μM) (Sigma-Aldrich, 
Poole, Dorset, UK) for [3H]SCH-23390,  [3H]raclopride and [3H]mazindol binding 
respectively.  Following a binding period of 60 min for MOP-r and 90 min, 60 min or 45 min 
for D1, D2 dopamine receptor and DAT respectively, and washing in ice cold buffer (3x5 min 
for MOP-r binding, 6x1 min for D1 and D2 dopamine receptor binding and 2x1 min for DAT 
binding), the slides were apposed to Kodak MR film (Sigma-Aldrich, Poole, Dorset, UK) for 
4 weeks for D1 and DAT binding and 3 weeks for MOP-r and D2 binding.  Sections from 
chronic saline and heroin treated C57BL/6J and DBA/2J mice were processed together in a 
paired protocol.  Films were developed using 50% Kodak D19 developer (Sigma-Aldrich, 
Poole, Dorset, UK).  Quantitative analysis of brain receptors was performed as detailed 
 8
previously (Kitchen et al. 1997; Lena et al. 2004) using an MCID image analyser (Image 
Research, Ontario, Canada) and brain structures were identified using the mouse brain atlas of 
Franklin and Paxinos (1997). 
 
μ- opioid receptor  (MOP-r) stimulated [35S]GTPγS binding autoradiography 
 
General procedures for MOP-r agonist-stimulated guanosine 5’-[γ-[35S]thio]-triphosphate 
([35S]GTPγS) autoradiography were performed essentially as described by Sim et al. (1996), 
Kirschke et al. (2002) and Bailey et al. (2004; 2007b).  Adjacent 20 μm coronal sections were 
cut at a interval of 300 μm from chronic saline or heroin treated C57BL/6J and DBA/2J mice 
brains for the determination of basal, DAMGO-stimulated [35S]GTPγS and non-specific 
binding.  Sections were preincubated in assay buffer (50 mM TrisHCl, 3 mM MgCl2.6H2O, 
0.2 mM EGTA, 100 mM NaCl, pH 7.4 at 25 oC) for 10 min.  Sections were then incubated in 
assay buffer containing 1 mM GDP (Sigma-Aldrich, Poole, Dorset, UK), pH 7.4 at 25 oC for 
15 min and rinsed in fresh assay buffer.  MOP-r agonist-stimulated activity was determined 
by incubating the sections in [35S]GTPγS (0.04 nM) (Perkin Elmer, Bucks, UK) with the 
selective μ- opioid receptor agonist DAMGO (5 μM) (Tocris Bioscience, Bristol, UK) for 2 h 
in assay buffer containing 1 mM GDP.  Basal G protein activity was determined by 
incubating the sections in [35S]GTPγS in the presence of GDP (1 mM) and in the absence of 
the agonist.  Non-specific binding was assessed by incubating sections with [35S]GTPγS in 
assay buffer in the presence of 10μM unlabelled GTPγS (Sigma-Aldrich, Poole, Dorset, UK).  
After incubation for 2 h, slides were rinsed twice for 3 min in ice cold buffer (50 nM TrisHCl, 
pH 7.4 at 0 oC) followed by one rinse in de-ionised water.  Slides were then dried for 2 h in a 
cold air stream and drying was continued for a further 2 days using anhydrous calcium 
sulphate (Drierite, BDH Chemicals, Poole, UK).  Sections from chronic saline and heroin 
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treated C57BL/6J and DBA/2J mice were apposed in a paired protocol to Kodak MR film 
together with [14C] standards (GE Healthcare Life Sciences, Bucks, UK) for 3 days.  
Quantitative analysis of optical density was performed as detailed previously (Schroeder et al. 
2003) using [14C] standards.  For each brain region examined, [35S]GTPγS binding was 
calculated by first subtracting the optical density of non-specific binding sections from the 
optical density of either agonist-stimulated or basal binding sections.  
 
Measurement of corticosterone plasma levels 
 
Chronic  “intermittent” saline and heroin treated C57BL/6J and DBA/2J mice were 
decapitated at the end of the treatment and trunk blood  from each animal was collected in 
tubes placed on ice, and was spun in a refrigerated centrifuge.  Plasma was separated and 
stored at -20oC for corticosterone measurements by radioimmunoassay. Corticosterone levels 
were assayed by using a rat/mouse corticosterone [125I] kit (MP Biomedicals, NY, NY, USA).  
All corticosterione levels were determined in duplicate in a single assay. 
 
Statistics 
 
For the conditioned place preference experiments, three-way ANOVA for factors strain, dose 
(saline, 0.5, 1, 2, 4, 8mg/kg heroin) and test (pre-conditioned, post-conditioned) with repeated 
measures for test, followed by the Newman-Keuls post hoc test was used for comparison of 
pre-conditioning and post-conditioning time spent in the drug paired compartment (shift in 
preference).  Two way ANOVA for factors dose and strain followed by the Newman-Keuls 
post hoc test was used for comparison of the change of time spent in heroin paired 
compartment.  Time spent by each strain in the white and black compartments of the heroin 
CPP apparatus during the preconditioning phase of the CPP study was analysed using the 
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nonparametric Mann-Whitney U test.  For ambulatory activity data in CPP experiments, 
three-way ANOVA for factors strain, dose and day (i.e. first day of conditioning and fourth 
day of conditioning) with repeated measures for the last variable, followed by the Newman-
Keuls post hoc test was used for comparison of ambulatory activity of C57BL/6J and DBA/2J 
mice on the first and fourth conditioning day of our CPP paradigm.  For the chronic escalating 
dose study, heroin-induced locomotor activity in 15 min bins was analysed by three-way 
analysis of variance (ANOVA) (for factors strain, treatment and day) with repeated measures 
for day, followed by Newman-Keuls post hoc test.  Three-way ANOVA (for factors strain, 
treatment and region) was used for comparison of quantitative measures of MOP-r, D1, D2 
receptors, DAT and MOP-r stimulated [35S]GTPγS binding in chronic saline and heroin 
treated C57BL/6J and DBA/2J brains followed by LSD post hoc test.  Comparison of plasma 
corticosterone levels in chronic  “intermittent” saline and heroin treated C57BL/6J and 
DBA/2J mice was performed using two-way ANOVA (for factors strain and treatment) 
followed by post hoc LSD test.  All values were expressed as mean ± S.E.M.  All statistical 
analysis was carried out with the use of statistical package “Statistica” (Bedford, Beds, UK) 
 
Results 
 
Heroin-induced conditioned place preference in C57BL/6J and DBA/2J mice 
 
Rewarding responses induced by heroin (0.5, 1, 2, 4 and 8 mg/kg, s.c.) were evaluated in 
C57BL/6J and DBA/2J mice using the place conditioning paradigm.  One-way ANOVA 
revealed a similar time spent in the drug associated compartment during the pre-conditioning 
phase in the different groups (C57BL/6J and DBA/2J) (P>0.05).  Moreover, neither 
C57BL/6J nor DBA/2J mice showed any unconditioned preference for either of the two 
compartments (black or white) of the apparatus used for heroin conditioned place preference 
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but spent less time in the smaller centre compartment ensuring the use of an apparatus 
unbiased procedure (Table 1).  Shifts in preference between preconditioning and post 
conditioning days after heroin treatment are shown in Suppl. 1. Three-way ANOVA showed a 
significant dose (F(5,152)=4.3, P<0.01), test (F(1,152)=101.6, P<0.001), strain x test interaction 
(F(1,152)=4.5, P<0.05) and a significant dose x test effect (F(5,152)=5.3, P<0.001).  The 
Newman-Keuls post hoc test showed that C57BL/6J mice developed CPP at 2, 4 and 8 mg/kg 
of heroin but not at 0.5 and 1 mg/kg (Suppl. 1).  C57BL/6J mice spent significantly more time 
in the drug paired compartment when they were paired with 2 mg/kg heroin compared to 0.5 
and 1 mg/kg heroin during the post conditioning phase (Newman-Keuls post hoc test) (Suppl. 
1).  However, DBA/2J mice developed CPP at 0.5, 1 and 2 mg/kg heroin (P<0.001), but not at 
4 and 8 mg/kg (P>0.05) (Suppl. 1).  DBA/2J mice spent significantly less time in the drug 
paired compartment when they were paired with 4 and 8 mg/kg heroin compared to 2 mg/kg 
heroin during the post-conditioning phase (Newman-Keuls post hoc test, Suppl. 1).  The 
change in time spent in heroin paired compartments are shown in Fig. 1.  Two-way ANOVA 
showed a significant strain (F(1,154)=4.5, P<0.05) and dose (F(5,154)=5.3, P<0.001) effects.  The 
results are similar to the ones presented above.  While C57BL/6J mice developed conditioned 
place preference to 2, 4 and 8 mg/kg of heroin but not at 0.5 and 1 mg/kg, DBA/2J mice 
developed conditioned place preference at 0.5, 1 and 2 mg/kg heroin, but not at 4 and 8 mg/kg 
(Fig. 1, Neuman Keuls post hoc test). 
 
Locomotor responses induced by heroin (0.5, 1, 2, 4 and 8 mg/kg, s.c.) were evaluated in 
C57BL/6J and DBA/2J mice during the first (day 1) and the last (day 4) day of the 
conditioning phase of our CPP paradigm.  Three way ANOVA showed a significant strain 
(F(1,132)=490.0, P<0.001), dose (F(5,132)=53.5, P<0.001), strain x dose interaction (F(1,132)=57.3, 
P<0.001), strain x day (F(1,132)=9.7, P<0.01), dose x day (F(5,132)=4.1, P<0.01) and strain x 
dose x day (F(5,132)=5.7, P<0.001) effects.  Newman Keuls post hoc test showed that heroin (1, 
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2, 4 and 8 mg/kg, s.c.) significantly increased ambulatory activity both on day1 (P<0.001) and 
day 4 (P<0.001) of the conditioning phase in C57BL/6J mice, but not in DBA/2J (P>0.05) 
(Fig. 2).  Moreover, repeated injections of heroin (2, 4 and 8 mg/kg, s.c.) resulted in a 
significant increase (P<0.01, Newman Keuls post hoc test) in ambulatory activity on day 4 of 
the conditioning phase compared to day1 in C57BL/6J mice, thus demonstrating the 
development of locomotor sensitisation.  Such sensitization effect was not observed at 0.5 and 
1 mg/kg heroin.  Heroin had no locomotor or sensitisation effect in DBA/2J mice at any dose 
tested (P>0.05) (Fig. 2). 
 
Heroin-induced locomotion in C57BL/6J and DBA/2J mice during chronic “intermittent” 
heroin administration  
 
Locomotor activity of naïve C57BL/6J and DBA/2J mice was measured 45 min after 
placement in the locomotor chambers for a 15 min duration on day 1 (Fig. 3).  One-way 
ANOVA, did not show any significant strain effect on basal locomotor activity (P>0.05).  
 
Locomotor activity of C57BL/6J and DBA/2J mice was measured after the second of the two 
daily injections of saline or heroin (1-8 mg/kg) from day 1 to day 7 of the chronic 
“escalating” dose heroin treatment (9 a.m.) (Fig. 3).  There was no significant difference in 
locomotor activity between saline treated C57BL/6J and DBA/2J mice at any day of the 
treatment protocol.   
 
Three-way ANOVA, for factors strain (C57BL/6J and DBA/2J), treatment (saline, heroin), 
day (day 1 through to day 7) with repeated measures on the last variable, showed a significant 
main effect of strain [F(1,188)=56.85, P<0.0001], treatment [F(1,188)=101.76, P<0.0001], day 
[F(6, 1128)=80.16, P<0.0001] and a significant strain x treatment x day interaction [F(6, 
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1128)=59.66, P<0.001].  Heroin injections significantly increased locomotor activity in 
C57BL/6J animals versus saline in a dose dependent manner (Fig. 3).  However, heroin did 
not increase locomotor activity of DBA/2J mice at any day or dose used in the treatment 
protocol (Fig.3).  The locomotor activity of heroin-treated C57BL/6J mice was significantly 
higher than that of DBA/2J mice on days 3-7.   
 
MOP-r receptor autoradiography in chronic heroin treated C57BL/6J and DBA/2J mice 
 
Quantitative analysis of MOP-r binding showed a significant treatment treatment (F1,251 = 
6.71, P < 0.05), strain (F1,251 = 7.52, P < 0.01), region x strain (F13,251 = 149.2, P < 0.001) and 
strain x treatment interaction (F1,251 = 9.10, P < 0.01).  LSD post hoc analysis showed a 
significant decrease in MOP-r binding in the nucleus accumbens shell (P<0.05), centromedial 
nucleus of the thalamus (P<0.05) and habenula (P<0.01) of chronic heroin treated C57BL/6J 
mice compared to saline controls (Fig. 4).  In contrast, chronic heroin treatment did not alter 
the density of MOP-r in any of the brain regions of DBA/2J mice analysed (Fig. 4).  
Moreover, significantly higher binding of MOP-r was observed in the nucleus accumbens 
core (P<0.05) and shell (P<0.05), the hypothalamus (P<0.05) and habenula (P<0.001) of 
chronic heroin treated DBA/2J mice compared to chronic heroin treated C57BL/6J mice (Fig. 
4).  Finally, there was significantly lower binding of MOP-r in the centromedial nucleus of 
the thalamus (P<0.05) and centrolateral nucleus of the thalamus (P<0.01) of chronic saline 
treated DBA/2J mice compared to saline treated C57BL/2J animals (Fig. 4).   
 
D1, D2 dopamine receptor and dopamine transporter (DAT) autoradiography in chronic heroin 
treated C57BL/6J and DBA/2J mice 
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In the case of DAT binding, three way ANOVA showed a significant main effect of strain 
strain (F1,95 = 13.3, P < 0.001) and a significant strain x treatment interaction (F1,95 = 8.8, P < 
0.01) with no significant treatment effect.  LSD post hoc analysis showed significantly higher 
levels DAT binding in the nucleus accumbens core of chronic heroin treated DB/2J mice 
compared to chronic saline treated DBA/2J mice (P < 0.05) (Fig. 5A, supplement 2).   Post 
hoc analysis also showed significantly higher levels of DAT binding in the nucleus 
accumbens shell  (P < 0.05), olfactory tubercle (P < 0.001) and caudate putamen (P<0.05) of 
chronic heroin treated DBA/2J mice compared to chronic heroin treated C57BL/6J mice.  In 
contrast to DBA/2J mice, no significant treatment effect was observed in any of the regions of 
C57BL/6J mice analysed (Fig. 5A).  In contrast to DAT binding, there was no significant 
strain or treatment or treatment x strain interaction effect of D1 or D2 dopamine receptor 
binding (Fig. 5 B, C supplement 2) (P>0.05). 
 
μ- opioid receptor stimulated [35S]GTPγS binding autoradiography in brains of chronic saline 
and heroin treated C57BL/6J and DBA/2J mice 
 
DAMGO (5 μM) stimulated [35S]GTPγS autoradiography was performed in coronal brain 
sections of chronic saline or heroin treated C57BL/6J and DBA/2J mice (Fig. 6) in order to 
investigate whether there are any alterations in MOP-r activity after chronic heroin 
administration.  Three-way ANOVA for factors strain, treatment and region showed a 
significant effect of strain (P<0.001) and strain x region interaction (P<0.01) with no 
significant treatment effect (Fig. 7).  Significantly higher levels of MOP-r stimulated 
[35S]GTPγS binding (around 100%) was observed in the nucleus accumbens core (P<0.05) 
and shell (P<0.05) of both saline and heroin treated C57BL/6J mice compared to DBA/2J 
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(Fig. 7).  Lower levels of MOP-r stimulated [35S]GTPγS binding (P<0.05) was also observed 
in the caudate putamen of saline treated DBA/2J mice compared saline treated C57BL/6J. 
  
Blood corticosterone levels in chronic saline and heroin treated C57BL/6J and DBA/2J mice 
 
Two way ANOVA showed a significant treatment effect (P<0.01) but no strain effect.  
Chronic heroin treatment decreased corticosterone levels in both C57BL/6J and DBA/2J mice 
(P<0.05, LSD post hoc test) (Fig. 8). 
 
Discussion 
 
The behavioural results in this study demonstrate profound differences in the sensitivity to the 
locomotor, sensitisation and rewarding effects of heroin, between C57BL/6J and DBA/2J 
mice suggesting that the sensitivity to heroin related addictive behaviours is genotype 
dependent.  While heroin significantly increased locomotor activity in C57BL/6J, it did not 
increase locomotion in DBA/2J mice, even at the highest dose of 8 mg/kg of our CPP and 
chronic “intermittent” escalating dose heroin administration paradigm.  Moreover, repeated 
administration of heroin at all but 0.5 and 1 mg/kg doses tested in our CPP paradigm induced 
locomotor sensitisation in C57BL/6J mice but not in DBA/2J, which indicates that C57BL/6J 
are sensitive and DBA/2J mice resistant to the locomotor and sensitisation effect of heroin.  
These results are consistent with studies showing that morphine induced strong locomotor and 
sensitisation responses in C57BL/6J mice, while DBA/2J mice are not stimulated at all 
(Oliverio & Castellano 1974a; 1974b; Brase et al. 1977; Belknap et al. 1989; Wenger 1989; 
Belknap et al. 1998; Orsini et al. 2005).  The fact that the locomotion and sensitization results 
obtained in our study with heroin, a synthetic opiate which is metabolized to MOP-r agonists 
morphine and 6-monoacetylmorphine, are in complete agreement and accordance with those 
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obtained by other groups with the use morphine, suggest that the locomotor and sensitization 
effects of both heroin and morphine are most likely to be mediated via the same mechanism, 
via MOP-r activation.  In support of this, it has been shown that both heroin and morphine 
lacked any kind of locomotor stimulation in MOP-r deficient mice (Matthes et al. 1996; 
Contarino et al. 2002).  However, this is not necessarily true for other opioid effects.  For 
instance Schuller et al., (1999) reported that heroin retained its analgesic effect in mutant mice 
with a targeted disruption of exon 1 of MOP-r, while morphine lost its analgesic response in 
these animals.   
 
C57BL/6J and DBA/2J mice also differed in their rewarding effect of heroin as measured 
with CPP.  Both C57BL/6J and DBA/2J mice showed significant rewarding responses to 2 
mg/kg heroin, whereas high doses of 4 and 8 mg/kg heroin were only rewarding in C57BL/6J 
mice.  At these high doses, heroin had no rewarding effect in DBA/2J mice.  In contrast, at the 
lower doses of 0.5 and 1 mg/kg, heroin was shown to be highly rewarding in DBA/2J mice, 
while it did not induce reward in C57BL/6J mice.  This inverted U-shaped dose response 
functional stimulation observed for the rewarding effect of heroin  in C57BL/6J and DBA/2J 
mice has also been reported in C57BL/6J mice (Schlussman et al. 2008). This shift in the dose 
response curve to the left observed in our study in DBA/2J mice indicates a higher sensitivity 
of the DBA/2J strain to the rewarding properties of heroin compared to C57BL/6J mice which 
seems paradoxic considering our locomotor data.   
 
These results are in agreement with morphine-induced CPP studies showing that DBA/2J 
mice display stronger CPP in response to morphine than C57BL/6J (Cunningham et al. 1992; 
Semenova et al. 1995) and in contrast with Orsini et al., (2005) who showed higher sensitivity 
for morphine in C57BL/6J mice compared to DBA/2J.  As differences between results could 
occur due to differences in experimental protocol, our study was designed to measure 
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locomotor and CPP behaviours during the same CPP session in the same animals.  Although 
different methodologies were used between our study and others (e.g. different apparatus bias, 
conditioning time), it is unlikely that the discrepancies observed are due to differences in the 
CPP protocol.  However, differences in environment conditions (e.g. stress) experienced by 
our DBA/2J mice compared to DBA/2J mice used by other groups may account for the 
discrepancies observed.  Indeed, it has been well demonstrated that behavioural effects of 
DBA/2J mice in response to amphetamine are highly dependent on environmental 
experiences (Cabib et al. 2000) and social isolation has also been shown to attenuate 
morphine induced CPP in male NMRI mice (Coudereau et al. 1997).  In our study, both 
C57BL/6J and DBA/2J mice were individually housed for at least 2 weeks before the CPP 
experiment begun, whereas in all the aforomentioned experiments, the mice were multiply 
housed in groups (4-12 animals per cage).  Moreover, acute opioid administration is well 
known to induce a stress response by activating the hypothalamic-pituitary-adrenal (HPA) 
axis activity in rodents (Buckingham & Cooper 1984; Fuertes et al. 2000).  As a result, we 
explored whether behavioural strain differences observed in response to heroin in our study 
are due to differential effect of heroin on HPA axis activity in the two strains of mice.  The 
stress hormone corticosterone was measured in the plasma of chronic heroin treated 
C57BL/6J and DBA/2J mice but no strain differences were observed.  Chronic heroin 
administration significantly decreased corticosterone in both C57BL/6J and DBA/2J mice 
which is a indication of the development of tolerance to the opioid stimulating effect on 
endocrine secretion which is consistent with the findings of Fuertes et al., (2000).  This result 
suggests that stress may not have influenced the behavioural response to heroin in DBA/2J 
mice. 
 
The lack of correlation between the rewarding and locomotor responses to heroin in 
C57BL/6J and DBA/2J mice supports the hypothesis that reward and locomotion are 
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distinctly separate responses regulated by distinct mechanisms.  The same may be true for 
other MOP-r mediated effects.  Interestingly, while DBA/2J mice are more sensitive to the 
analgesic responses of morphine (Semenova et al. 1995), C57BL/6J mice showed greater 
morphine consumption compared to DBA/2J mice (Crabbe & Belknap 1992) suggesting that 
the analgesic and self administration effect of opioids are also regulated by distinct 
mechanisms.  
 
As profound differences were observed in the behavioural effects of heroin in C57BL/6J and 
DBA/2J mice, we carried out further studies in order to investigate the neurobiological basis 
that might underlie some of these differences.  Interestingly, different effects were observed 
between MOP-r and MOP-r stimulated G protein activity in our study.  While a profound 
strain differences in MOP-r activity was observed in C57BL/6J mice compared to DBA/2J 
with a two fold reduced MOP-r activity observed in the nucleus accumbens and caudate 
putamen of saline treated DBA/2J mice vs C57BL/6J, this was not accompanied by a decrease 
in MOP-r density.  However, C57BL/6J and DBA/2J mice differed in their regulation of 
MOP-r by heroin which is in accordance with Pertuzzi et al., (1997) who reported similar 
results for morphine.  Heroin decreased MOP-r’s binding  in the nucleus accumbens shell, 
centromedial thalamus and habenula of C57BL/6J mice, but not in DBA/2J.  No heroin-
induced regulation of MOP-r G protein activity was observed in any brain regions of 
C57BL/6J or DBA/2J mice.  These results show the importance of determining functional 
activity of receptor systems, demonstrating that downregulation in receptor density does not 
necessarily translate into loss of functional activity which is consistent with our recent study 
where a decrease in D2 dopamine receptor density was accompanied by an increase in D2 
receptor activity in the striatum of mice treated with an escalating dose “binge” cocaine 
administration protocol (Bailey et al. 2008).  The substantially reduced levels of MOP-r 
stimulated G protein activity observed in the caudate putamen, which is a region well known 
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to be linked with locomotor activity (Angulo & McEwen 1994) of DBA/2J mice compared to 
C57BL/6J mice, could partially explain the strain differences in locomotor stimulating 
phenotype in response to opiates.  Maher et al., (2005) showed that even a 30 % decrease in 
MOP-r stimulated [35S]GTPγS binding produced a 7.5 fold increase in the concentration of 
heroin necessary to produce this level of G protein activation.  Different expression of G 
protein subunits between strains may account for differences in MOP-r G protein activation 
observed in our study.  Indeed, a recent microarray study revealed differences in G protein 
subunit expression between the nucleus accumbens of C57BL/6J and DBA/2J mice (Grice et 
al. 2007).  Overall, our results imply that the ability of heroin to induce MOP-r activity in 
specific brain regions might be an important factor in individual’s vulnerability to develop 
heroin addiction.  This is in complete agreement with Bond et al., (1998) and Kroslak et al., 
(2007) who showed that A118G human variant of MOP-r which has been associated with 
opioid addiction (LaForge et al. 2000) has significantly higher affinity and potency to activate 
G-protein coupled inward rectifying potassium channels by opioids compared to the prototype 
receptor. 
  
Higher density of DAT binding was observed in the caudate putamen, the olfactory tubercle 
and the nucleus accumbens shell of chronic heroin treated DBA/2J mice compared to heroin 
treated C57BL/6J, indicating a strain difference in the regulation of DAT following chronic 
heroin treatment.    By removing extracellular dopamine and recycling it back into the neuron, 
DAT plays a key role in regulating neurotransmission in the dopaminergic system (Gulley & 
Zahniser 2003).  Mice lacking DAT have been shown to be hyperactive and have enhanced 
dopaminergic neurotransmission and increased extracellular dopamine levels in the striatum 
(Giros et al. 1996; Jones et al. 1998; Spielewoy et al. 2000).  As a result, our data suggests 
that C57BL/6J mice may have enhanced striatal dopaminergic neurotransmission and 
extracellular dopamine levels in response to heroin compared to DBA/2J mice, due to 
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differences in striatal DAT density.  Differences in dopamine neurotransmission have been 
observed following acute morphine administration in C57BL/6J and DBA/2J mice.  
Microdialysis studies showed that although no strain differences in basal extracellular 
dopamine levels were observed, C57BL/6J mice had higher increases in ventral and dorsal 
striatal extracellular dopamine levels in response to morphine compared to DBA/2J mice 
(Murphy et al. 2001; Fadda et al. 2005).  However, as the effect of drugs of abuse on the 
dopaminergic system are well known to differ when the drug is administered acutely 
compared to chronic administration (Unterwald et al. 1994; Maisonneuve et al. 1995), it is 
difficult to make conclusions on the state of dopaminergic neurotransmission in chronically 
heroin treated C57BL/6J and DBA/2J mice, based on the acute microdialyis study alone.  
However, the increase of locomotor effect of heroin in C57BL/6J mice compared to DBA/2J 
mice, which is generally though to be under striatal dopaminergic control (Murphy et al. 
2001), together with the differential regulation of DAT by chronic heroin treatment in 
C57BL/6J mice vs DBA/2J, clearly indicates an enhancement of limbic dopamine 
neurotransmission in chronically heroin treated C57BL/6J vs DBA/2J mice.  As a result, it is 
likely that the strain differences in the regulation of DAT by chronic heroin treatment may 
partially be responsible for some of the behavioural strain differences (at least the chronic 
locomotor behavioural effects).  This possibility though requires further investigation.   
 
In contrast to DAT and MOP-r, there was no strain or treatment effect on D1 and D2 dopamine 
receptor binding which suggests that the chronic locomotor behavioural strain differences 
observed in response to heroin are neither due to differences in D1 or D2 expression between 
strains nor to differences in regulation of  D1 or D2 receptors by heroin.   
 
Interestingly, although strain differences were observed in DAT binding of chronic heroin 
treated mice, no strain difference in DAT, D1 or D2 binding were observed between chronic 
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saline treated mice.  This is in contrast with De Jong et al., (2008) who showed higher levels 
of DAT mRNA and D1 receptor binding levels and lower D2 receptor binding levels in brain 
regions of drug naïve DBA/2J mice compared to C57BL/6J mice.  These discrepancies are 
likely to be caused by differences in animal treatment protocol (chronic saline treatment vs 
treatment naïve mice) or also by differences in the autoradiography protocol (e.g. different 
radioligands used, mRNA vs binding levels ect). 
 
Finally, the possibility that the interstrain behavioural and neurochemical variations observed 
in response to chronic heroin treatment in the present study could be due to pharmacokinetic 
differences between the two strains is worthy of consideration.  Although reports vary, up to 
40% higher concentrations of the heroin metabolite morphine have been found in brains of 
C57BL/6J mice compared to DBA/2J mice following peripheral administration (Brase et al. 
1977; Gwynn & Domino 1984; Belknap et al. 1989).  However, studies covering large 
numbers of varied strains drew no correlation between brain concentration and morphine 
sensitivity to the thermal analgesia (hot plate) and locomotor activity properties of morphine 
in these strains of mice (Belknap et al. 1998).  Moreover, an explanation of the strain 
differences in heroin-induced behaviours based only on pharmacokinetic differences is further 
undermined by the fact that an 8 fold increase in heroin dose had absolutely no locomotor 
stimulatory effect in DBA/2J mice in our study. 
 
In conclusion, the present results demonstrate that C57BL/6J and DBA/2J mice differ 
considerably in their sensitivity to the locomotor, sensitisation and rewarding effect of heroin 
indicating that the pharmacological effects of heroin is genotype dependent.  The profound 
strain differences observed in MOP-r G protein activity and in heroin induced regulation of 
DAT expression may be responsible for some of these behavioural differences (at least the 
chronic locomotor behavioural effects).  As a result these strains of mice may be useful in 
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identifying factors which would influence individuals’ vulnerability to develop opiate 
addiction. 
 
Table. 1 
Time spent by C57BL/6J and DBA/2J mice in the black, white and null zone compartments of 
the heroin conditioned place preference apparatus during the last 15 min of a 20 min exposure 
to the entire apparatus (preconditional test) 
Strain Black White null 
C57BL/6J 343.8±38.4 422.5±47.2 135.2±19.3 
DBA/2J 416.3±39.0 395.9±53.7 89.1±12.1 
Values represent mean±S.E.M of 83-85/strain.    
 
Legend to Figure 1.  Change in time spent in heroin paired compartment in C57BL/6J and 
DBA/2J mice.  Place conditioning was induced by the administration of 0.5 mg/kg heroin 
(C57BL/6J, n = 16; DBA/2J, n = 11), 1 mg/kg heroin (C57BL/6J, n = 15; DBA/2J, n = 9), 2 
mg/kg heroin (C57BL/6J, n = 15; DBA/2J, n = 14), 4 mg/kg heroin (C57BL/6J, n = 16; 
DBA/2J, n = 25) and 8 mg/kg heroin (C57BL/6J, n = 15; DBA/2J, n = 13) (s.c.).  Saline 
controls (C57BL/6J, n = 10; DBA/2J, n = 7) were included.  All values are expressed as mean 
± SEM.  * P<0.05,  ** P<0.01 vs 0 mg/kg heroin 
 
Legend to figure 2.  Locomotor sensitization in C57BL/6J and DBA/2J mice.  The locomotor 
effect of repeated saline (C57BL/6J, n = 10; DBA/2J, n = 7), 0.5 mg/kg heroin (C57BL/6J, n 
= 16; DBA/2J, n = 11), 1 mg/kg heroin (C57BL/6J, n = 15; DBA/2J, n = 9), 2 mg/kg heroin 
(C57BL/6J, n = 15; DBA/2J, n = 14), 4 mg/kg heroin (C57BL/6J, n = 16; DBA/2J, n = 25) 
and 8 mg/kg heroin (C57BL/6J, n = 15; DBA/2J, n = 13) (s.c.) was evaluated in C57BL/6J 
and DBA/2J mice during the first (Day 1) and the last day (Day 4) of the conditioning phase 
of our CPP paradigm.  ** P<0.01 vs  Day 1 (Newman Keuls post hoc test). 
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 Legend to Figure 3.  Locomotor activity in C57BL/6J and DBA/2J mice after an injection of 
saline or heroin during a chronic “intermittent” escalating dose administration paradigm.  The 
locomotor data were collected daily in 15 min bins following the second (i.e. 9 a.m.) of the 
two injections of an “intermittent” escalating dose (1-8 mg/kg, s.c.) pattern of heroin or saline.  
Responses are shown on day 1 through to day 7.  Basal locomotor activity for 15 min duration 
after 45 min placement of mice in the locomotor chamber is shown at time 0 for each group of 
mice during every day of the treatment protocol.  The arrow indicated the time of injection of 
saline or heroin.  Values are mean ± S.E.M of 6 animals in each group.  *P<0.05, **P<0.01, 
***P<0.001 vs saline C57BL/6J on the same day 
 
Legend to Figure 4.  A. Quantitative autoradiography  of MOP-r binding in coronal brain 
sections from chronically “intermittent” escalating dose heroin or saline treated C57BL/6J 
and DBA/2J mice.  Data are expressed as the mean specific binding (fmol/mg)  ± S.E.M of 6 
determinants (n=6) of [3H]DAMGO in brain regions of  chronically heroin and saline treated 
C57BL/6J and DBA/2J mice.  Regional determinations were made from both left and right 
sides of the sections.  The labelling was carried out on sections from chronically heroin and 
saline treated C57BL/6J and DBA/2J mice in a completely paired protocol  * P<0.05, ** 
P<0.01 vs saline C57BL/6J;   # P<0.05, ### P<0.001 vs C57BL/6J heroin; (LSD post hoc test).  
B) Computer-enhanced autoradiograms of coronal brain sections from chronically 
“intermittent” escalating dose heroin or saline treated C57BL/6J and DBA/2J mice.  The 
adjacent sections shown are from the level of the caudate (Bregma 1.34 mm).  The colour bar 
represents a pseudo-colour interpretation of  black and white film images in fmol/mg tissue 
equivalent.  Sections cut from chronically heroin and saline treated C57BL/6J and DBA/2J 
mice brains were processed in parallel.  See list of abbreviations. 
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Legend to Figure 5.  Quantitative autoradiography of D1, D2 dopamine receptor and dopamine 
transporters binding in coronal brain sections from chronically “intermittent” escalating dose 
heroin and saline treated C57BL/6J and DBA/2J mice.  Data are expressed as the mean 
specific binding (fmol/mg)  ± S.E.M of 5-6 determinants  of A) [3H]mazindol,  B) 
[3H]raclopride and C) [3H]SCH-23390 in brain regions of  chronically heroin or saline treated 
C57BL/6J and DBA/2J mice.  Regional determinations were made from both left and right 
sides of the sections.  The labelling was carried out on sections from chronically heroin or 
saline treated C57BL/6J and DBA/2J mice  in a completely paired protocol.  Specific binding 
was >80 % in all regions analysed.  * P<0.05 vs saline DBA/2J ; # P<0.05, ### P<0.001 vs 
heroin C57BL/6J,   (LSD post hoc test).  See list of abbreviations. 
 
Legend to Figure 6. Computer-enhanced autoradiograms of coronal brain sections from 
chronic “intermittent” escalating dose heroin and saline treated C57BL/6J and DBA/2J mice.  
The sections shown are from the level of the caudate (Bregma 1.10 mm) (columns 1 and 2) 
and from the level of the hippocampus (Bregma –1.58 mm) (columns 3 and 4).  Sections were 
preincubated with 1 mM GDP and then incubated for 2 h with [35S]GTPγS (0.04 nM) and 1 
mM GDP (basal) or with [35S]GTPγS (0.04 nM) and 1 mM GDP in the presence of DAMGO 
(5 μM) (MOP-r stimulated [35S]GTPγS).  The colour bar represents a pseudo-colour 
interpretation of relative black and white film images.   Sections cut from chronic 
“intermittent” escalating dose heroin and saline treated C57BL/6J and DBA/2J mice brains 
were processed in parallel 
 
Legend to Figure 7.  DAMGO stimulated [35S]GTPγS binding in coronal brain sections from 
chronically heroin and saline treated C57BL/6J and DBA/2J mice.  Data are expressed as 
mean ± S.E.M (n=6-11) of increase of [35S]GTPγS binding from basal (KBq/mg).  *P<0.05 vs 
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saline treated C57BL/6J mice,  #P<0.05; ##P<0.01  vs heroin treated C57BL/6J mice (LSD 
post hoc test).  See list of abbreviations. 
 
Legend to Figure 8. Effect of chronic “intermittent” heroin administration on plasma 
corticosterone levels of C57BL/6J and DBA/2J mice.  Data are expressed as mean ± S.E.M 
(n=6).  A significant treatment effect was observed (P<0.01) but no strain effect.  * P<0.05 vs 
Saline (LSD post hoc test) 
 
Legend to Supplement 1.  Shift in time in the heroin-paired compartment during the post 
conditioning day compared to the preconditioning day in C57BL/6J and DBA/2J mice as 
measured in the CPP paradigm.  Place conditioning was induced by the administration of 0.5 
mg/kg heroin (C57BL/6J, n = 16; DBA/2J, n = 11), 1 mg/kg heroin (C57BL/6J, n = 15; 
DBA/2J, n = 9),  2 mg/kg heroin (C57BL/6J, n = 15; DBA/2J, n = 14), 4 mg/kg heroin 
(C57BL/6J, n = 16; DBA/2J, n = 25) and 8 mg/kg heroin (C57BL/6J, n = 15; DBA/2J, n = 13) 
(s.c.).  Saline controls (C57BL/6J, n = 10; DBA/2J, n = 7) were included.  All values are 
expressed as mean ± SEM.  * P<0.05,  ** P<0.01, *** P<0.001 vs preconditioning;  # P<0.05,  
### P<0.001 vs 2 mg/kg heroin post-conditioning);  Τ P<0.05, ΤΤP<0.01, ΤΤΤP<0.001 vs saline 
postconditioning (Newman Keuls post hoc test). 
 
Legend to Suplement 2.  Computer-enhanced autoradiograms of coronal brain sections from 
chronically “intermittent” escalating dose heroin or saline treated C57BL/6J and DBA/2J 
mice. The adjacent sections shown are from the level of the caudate (Bregma 1.34 mm).  
Dopamine transporters (DAT), D2 and D1 dopamine receptor were labelled with [3H]mazindol 
(4 nM), [3H]raclopride (4 nM) and [3H]SCH-23390 (4 nM) respectively.  The colour bar 
represents a pseudo-colour interpretation of black and white film images in fmol/mg tissue 
 26
equivalent.  Sections cut from chronically heroin and saline treated C57BL/6J and DBA/2J 
mice brains were processed in parallel. 
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Abbreviations: FCx; prefrontal cortex; CgCx, Cingulate cortex; AcbC, Nucleus accumbens 
core; AcbSh, Nucleus accumbens shell; Tu, Olfactory tubercle; Den, Dorsal endopiriform; 
CPu, Caudate putamen; MS, medial septum; VDB, vertical limb diagonal band; Re, Reuniens; 
CMTh, central medial thalamic nuclei; CLTh, central lateral thalamic nuclei; Hy, 
Hypothalamus; Amy, Amygdala; Ha, habenula; PrLCx, Prelimbic cortex; SN, Substantia 
nigra; STh, Subthalamic nucleus; MCx, motor cortex; ANOVA, analysis of variance; MOP-r, 
μ- opioid receptors; DAT, dopamine transporter; Gi/o, G- ptrotein; CPP: Conditioned Place;  
Preference; GTPγS, guanosine 5’-[γ-[35S]thio]-triphosphate; DAMGO, D-Ala2-MePhe4-Gly-
ol5 enkephalin; s.c, subcutaneously; HPA, hypothalamic pituitary adrenal axis  
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